This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Novo Nordisk's performance against key rivals in the ethical pharmaceutical sector See how a significant presence in the fast-growing diabetes therapy area will help drive the company's growth over the forecast period Learn how the company's dependency on therapeutic proteins and focus on market-leading administration devices insulates it from biosimilar competition